IP Library Granted Patent US 8,637,077
Granted Patent B2
US 8,637,077 · App. 10/451,922 · Granted Jan 28, 2014

Sustained-release preparation

Inventors: Shigeyuki Takada (Nishinomiya, JP); Masafumi Misaki (Takarazuka, JP); Kenji Nakamura (Itami, JP)
Assignee: Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,637,077
App. No.
10/451,922
Granted
Jan 28, 2014
Kind
B2
Abstract

Sustained release preparations, which show suppressed initial release of a physiologically active substance and can release a constant amount of the physiologically active substance over a long period of time, and dispersion vehicle thereof can be obtained by adding a cationic substance or polyols to the outside of a matrix or dispersion vehicle thereof. Thus, sustained release preparations, which show suppressed initial release of a physiologically active substance immediately after the administration and can release a constant amount of the physiologically active substance over a long period of time and dispersion vehicle thereof can be provided.

Claims (20)

1. A sustained-release preparation wherein the initial release of a bioactive substance is suppressed, comprising a combination of a microcapsule containing the bioactive substance and a biodegradable polymer having a weight-average molecular weight of about 3,000 to about 50,000, and a dispersion vehicle containing a basic amino acid and a polyethyleneglycol, wherein the dispersion vehicle is a water-soluble medium for suspension of the microcapsule used for injection and the basic amino acid and the polyethyleneglycol do not exist in the microcapsule and exist outside the microcapsule or on the outer surface of the microcapsule;

and wherein the basic amino acid and polyethyleneglycol suppress the initial release of the bioactive substance.

2. The sustained-release preparation according to claim 1 , wherein the basic amino acid is arginine or lysine.

3. The sustained-release preparation according to claim 1 , wherein the bioactive substance is a bioactive peptide.

4. The sustained-release preparation according to claim 3 , wherein the bioactive peptide has a molecular weight of about 200 to about 500,000.

5. The sustained-release preparation according to claim 3 , wherein the bioactive peptide has a molecular weight of about 5,000 to about 500,000.

6. The sustained-release preparation according to claim 3 , wherein the bioactive peptide is a hormone, a cytokine, a hematopoietic factor, a growth factor or an enzyme.

7. The sustained-release preparation according to claim 3 , wherein the bioactive peptide is a human growth hormone.

8. The sustained-release preparation according to claim 1 , wherein the biodegradable polymer is a homopolymer or a copolymer of α-hydroxycarboxylic acids, or a mixture thereof.

9. The sustained-release preparation according to claim 1 , wherein the biodegradable polymer is a copolymer having a composition ratio of lactic acid/glycolic acid of about 100/0 to about 40/60 mol %.

10. The sustained-release preparation according to claim 1 , wherein the biodegradable polymer is a homopolymer of lactic acid.

11. A dispersion vehicle containing a basic amino acid and a polyethyleneglycol, which is for the production of the sustained-release preparation used for injection according to claim 1 .

12. The sustained-release preparation according to claim 1 , wherein the bioactive substance is a powder obtained by lyophilization of a solution containing the bioactive substance whose concentration of an alkaline metal ion is adjusted to not more than about 10 μg/mL.

13. The sustained-release preparation according to claim 12 , wherein the powder is a microparticle.

14. The sustained-release preparation according to claim 13 , wherein the weight-average particle diameter of the powder is about 0.5 μm to about 2.0 μm.

15. The sustained-release preparation according to claim 12 , wherein the bioactive substance is a bioactive peptide.

16. The sustained-release preparation according to claim 12 , wherein the bioactive peptide is a hormone, a cytokine, a hematopoietic factor, a growth factor or an enzyme.

17. The sustained-release preparation according to claim 12 , wherein the bioactive peptide is a human growth hormone.

18. A method for suppressing the initial release of a bioactive substance in a sustained release preparation, comprising mixing a dispersion vehicle containing a basic amino acid and a polyethyleneglycol with a microcapsule containing the bioactive substance and a biodegradable polymer having a weight-average molecular weight of about 3,000 to about 50,000, wherein the dispersion vehicle is a water-soluble medium for suspension of the microcapsule containing the bioactive substance and the biodegradable polymer used for injection; and said sustained-release preparation comprises a combination of the microcapsule and the dispersion vehicle, and the basic amino acid and the polyethyleneglycol in the sustained-release preparation do not exist in the microcapsule and exist outside the microcapsule or on the outer surface of the microcapsule;

and wherein the basic amino acid and polyethyleneglycol suppress the initial release of the bioactive substance.

Assignments (2)
CHANGE OF NAME Recorded Nov 1, 2004
From: TAKEDA CHEMICAL INDUSTRIES, LTD.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 015943/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 27, 2003
From: TAKADA, SHIGEYUKI; MISAKI, MASAFUMI; NAKAMURA, KENJI
To: TAKEDA CHEMICAL INDUSTRIES, LTD.
Reel/Frame 014643/0694 →
Priority Claims (1)
JP 2000-402157 · Dec 28, 2000 · national
Continuity (1)
Related Publication 20040057996A1 · Mar 25, 2004